

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM357688

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	GRANT OF SECURITY INTEREST IN UNITED STATES TRADEMARK		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Nektar Therapeutics		10/05/2015	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	TC Lending, LLC, as collateral agent		
Street Address:	301 Commerce Street		
Internal Address:	Suite 3300		
City:	Fort Worth		
State/Country:	TEXAS		
Postal Code:	76102		
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE		
PROPERTY NUMBERS Total: 8			
Property Type	Number	Word Mark	
Serial Number:	86147364	INVVEOX	
Serial Number:	85724646	IT'S ABOUT TIME	
Serial Number:	78157780	NEKTAR	
Serial Number:	78157784	NEKTAR	
Serial Number:	85592487	NEKTAR	
Serial Number:	77978284	NEKTAR	
Serial Number:	86433872	ONZEALD	
Serial Number:	86571263	TEPTOLZA	
CORRESPONDENCE DATA			
Fax Number:	2125935955		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	212-756-2132		
Email:	scott.kareff@srz.com		
Correspondent Name:	S. Kareff c/o Schulte Roth & Zabel LLP		
Address Line 1:	919 Third Avenue		
Address Line 2:	25th Floor		
Address Line 4:	New York, NEW YORK 10022		
ATTORNEY DOCKET NUMBER:	079464-0057		

CH \$215.00 86147364

NAME OF SUBMITTER:	Scott Kareff (079464-0057)
SIGNATURE:	/kc for sk/
DATE SIGNED:	10/06/2015
Total Attachments: 7 source=Trademark Grant of Security Interest for Nektar Therapeutics#page1.tif source=Trademark Grant of Security Interest for Nektar Therapeutics#page2.tif source=Trademark Grant of Security Interest for Nektar Therapeutics#page3.tif source=Trademark Grant of Security Interest for Nektar Therapeutics#page4.tif source=Trademark Grant of Security Interest for Nektar Therapeutics#page5.tif source=Trademark Grant of Security Interest for Nektar Therapeutics#page6.tif source=Trademark Grant of Security Interest for Nektar Therapeutics#page7.tif	

**GRANT OF SECURITY INTEREST
IN UNITED STATES TRADEMARKS**

FOR GOOD AND VALUABLE CONSIDERATION, receipt and sufficiency of which are hereby acknowledged, Nektar Therapeutics, a Delaware corporation (the “Grantor”) with principal offices at 455 Mission Bay Blvd South, San Francisco, CA 94158, hereby grants to TC Lending, LLC, as Collateral Agent, with principal offices at 301 Commerce Street, Suite 3300, Fort Worth, TX 76102, (the “Grantee”), a continuing security interest in (i) all of the Grantor’s right, title and interest in, to and under to the United States trademarks, trademark registrations and trademark applications (the “Marks”) set forth on Schedule A attached hereto, (ii) all proceeds (as such term is defined in the Uniform Commercial Code of the State of New York as in effect from time to time) and products of the Marks, (iii) the goodwill of the businesses with which the Marks are associated and (iv) all causes of action arising prior to or after the date hereof for infringement of any of the Marks or unfair competition regarding the same.

THIS GRANT is made to secure the satisfactory performance and payment of all the Obligations of the Grantor, as such term is defined in the Pledge and Security Agreement among the Grantor, the other Grantors from time to time party thereto and the Grantee, dated as of October 5, 2015 (as amended, modified, restated and/or supplemented from time to time, the “Security Agreement”). Upon the occurrence of the Termination Date (as defined in the Security Agreement), the Grantee shall execute, acknowledge, and deliver to the Grantor an instrument in writing releasing the security interest in the Marks acquired under this Grant.

This Grant has been granted in conjunction with the security interest granted to the Grantee under the Security Agreement. The rights and remedies of the Grantee with respect to the security interest granted herein are as set forth in the Security Agreement, all terms and provisions of which are incorporated herein by reference. In the event that any provisions of this

Grant are deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

[Remainder of this page intentionally left blank; signature page follows]


IN WITNESS WHEREOF, the undersigned has executed this Grant as of the 5th day of
October, 2015.

NEKTAR THERAPEUTICS, Grantor

By *Gil M. Labrucherie*
Name: **Gil M. Labrucherie**
Title: **SVP & General Counsel**

IN WITNESS WHEREOF, the undersigned has executed this Grant as of the 5th day of
October, 2015.

TC LENDING, LLC,
as Collateral Agent and Grantee

By 

Name: Michael Fishman
Title: co-CEO

(see attached)

Nektar Therapeutics
Trademarks

Jurisdiction	Mark	Status	Serial No Filing Date	Reg. No. Reg. Date	Owner	Class/Description
United States	INVEEOX	Allowed	86147364 Dec 18, 2013		Nektar Therapeutics	05 Pharmaceutical preparations, namely, an anti-cancer agent.
United States	ITS ABOUT TIME	Allowed	85724646 Sep 10, 2012		Nektar Therapeutics	05 Pharmaceuticals, namely, pharmaceutical preparations having enhanced drug performance for the treatment and prophylaxis of pain and of nerve diseases.
United States	NEKTAR	Registered	78157780 Aug 26, 2002	3068889 Mar 14, 2006	Nektar Therapeutics	05 Pharmaceuticals, namely, pharmaceutical preparations having enhanced drug performance and/or drug delivery performance for the treatment and/or prophylaxis of diseases or medical conditions such as diabetes, infections, cancers, and inflammations; or of diseases or medical conditions that affect the peripheral nerves; the adrenergic and/or cholinergic receptors; the histamine receptors; the expression and/or regulation of growth factors; the skeletal and/or smooth muscle systems; the cardiovascular system; the endocrine and/or hormone systems; the blood circulatory system; the immunological system; the synaptic and neuroeffector junctional sites; the reproductive system; the skeletal system; the autocooid system; the alimentary and/or excretory systems; and/or the central nervous system.
United States	NEKTAR	Registered	78157784 Aug 26, 2002	2821781 Mar 9, 2004	Nektar Therapeutics	42 Research services, namely, providing research and development services for others in the biotechnical, biomedical and pharmaceutical fields.

Nektar Therapeutics
Trademarks

Jurisdiction	Mark	Status	Serial No Filing Date	Reg. No. Reg. Date	Owner	Class/Description
United States	NEKTAR (Stylized) NEKTAR	Allowed	85592487 Apr 9, 2012		Nektar Therapeutics	05 Pharmaceuticals, namely, pharmaceutical preparations having enhanced drug performance for the treatment of medical conditions in the nature of cancer; pharmaceuticals, namely, pharmaceutical preparations having enhanced drug performance for the treatment of medical conditions affecting peripheral nerves and peripheral nerve pain; pharmaceuticals, namely, pharmaceutical preparations having enhanced drug performance for the treatment of medical conditions affecting the central nervous system and pain in the central nervous system.
United States	NEKTAR (Stylized) NEKTAR	Registered	77978284 Jun 30, 2008	3735262 Jan 5, 2010	Nektar Therapeutics	42 Research services, namely, providing research and development services for others in the biotechnical, biomedical and pharmaceutical fields.
United States	ONZEALD	Allowed	86433872 Oct 24, 2014		Nektar Therapeutics	05 Pharmaceutical preparations, namely an anti-cancer agent.
United States	TEPTOLZA	Published	86571263 Mar 20, 2015		Nektar Therapeutics	05 Pharmaceutical preparations, namely, an anti-cancer agent.